A tale of two variants: Spread of SARS-CoV-2 variants Alpha in Geneva, Switzerland, and Beta in South Africa

Several SARS-CoV-2 variants of concern (VOC) are spreading rapidly in different regions of the world. The underlying mechanisms behind their transmission advantage remain unclear. We measured viral load in 950 individuals and found that infections with variant Alpha exhibit a higher viral load and longer viral shedding compared to non-VOC. We then used a transmission model to analyze the spread of variant Alpha in Geneva, Switzerland, and variant Beta in South Africa. We estimated that Alpha is either associated with a 37% (95% compatibility interval, CI: 25-63%) increase in transmissibility or a 51% (95% CI: 32-80%) increase of the infectious duration, or a combination of the two mechanisms. Assuming 50% immune evasion for Beta, we estimated a 23% (95% CI: 10-37%) increase in transmissibility or a 38% (95% CI: 15-78%) increase of the infectious duration for this variant. Beta is expected to outgrow Alpha in regions where the level of naturally acquired immunity from previously circulating variants exceeds 20% to 40%. Close monitoring of Alpha and Beta in regions with different levels of immunity will help to anticipate the global spread of these and future variants.

[1]  G. Biele,et al.  Estimating infectiousness throughout SARS-CoV-2 infection course , 2021, Science.

[2]  M. Suchard,et al.  Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil , 2021, Science.

[3]  S. Merler,et al.  Co-circulation of SARS-CoV-2 variants B.1.1.7 and P.1 , 2021, medRxiv.

[4]  T. Ndung’u,et al.  Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma , 2021, Nature.

[5]  Graham W. Taylor,et al.  Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Nature.

[6]  T. de Oliveira,et al.  New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications , 2021, The New England journal of medicine.

[7]  N. G. Davies,et al.  Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.

[8]  William T. Harvey,et al.  Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.

[9]  Timothy M. Sykes,et al.  Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland , 2021, Epidemics.

[10]  Sergei L. Kosakovsky Pond,et al.  Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.

[11]  M. Shankar-Hari,et al.  Virological and serological characterization of critically ill patient with COVID-19 in the UK: a special focus on variant detection , 2021, medRxiv.

[12]  D. Moodley,et al.  Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant , 2021, medRxiv.

[13]  A. Flahault,et al.  Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak , 2021, The Lancet Infectious Diseases.

[14]  L. Morris,et al.  SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, bioRxiv.

[15]  J. Farrar,et al.  Increased infections, but not viral burden, with a new SARS-CoV-2 variant , 2021 .

[16]  Carl A. B. Pearson,et al.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.

[17]  S. Yerly,et al.  SARS-CoV-2 viral load in the upper respiratory tract of children and adults with early acute COVID-19 , 2020, medRxiv.

[18]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[19]  C. Faes,et al.  Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[20]  S. Greenland,et al.  Scientists rise up against statistical significance , 2019, Nature.

[21]  Yuelong Shu,et al.  GISAID: Global initiative on sharing all influenza data – from vision to reality , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[22]  Wilco Keulen,et al.  Estimating Relative Fitness in Viral Competition Experiments , 2000, Journal of Virology.